Track the LIGAND PHARMACEUTICALS INCORPORATED share price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €5.7bn. The latest transaction was reported on 3 September 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ANDREW REARDON. All data is free.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LIGAND PHARMACEUTICALS INCORPORATED Strong Buy (bullish), based on 11 analysts. Average price target: US$342.82.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,205 of 29,062 companies
57.3
score / 100
Value
33
Quality
82
FCF yld0.7%
Earn yld2.2%
EV/EBITDA31.0x
ROE22%
Gross mgn95%
Net mgn46%
Debt/EBITDA2.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
4,519 shares@ US$250.8765100.0% of flowCommonSEC144:0001950047-26-005862
7 of 7 declarations
Acerca de LIGAND PHARMACEUTICALS INCORPORATED
LIGAND PHARMACEUTICALS INCORPORATED es una empresa biofarmacéutica centrada en el desarrollo de fármacos y tecnologías para las industrias farmacéutica y biofarmacéutica. Cotiza en el NASDAQ bajo el símbolo LGND.